Capsule Shell Manufacture
Figure 4.1Photograph of the Technophar capsule manufacturing machine. Hard capsule shell manufacturing remained almost exclusively in the United States from the 1880s until after the Second World War. Eli Lilly…
Non-Gelatin-Based Capsules
Figure 5.1Sorption isotherm data (absorption and desorption) of gelatin and HPMC (Vcaps® Plus) capsules stored at different RH values. (Courtesy of Capsugel.) The mechanical resistance and stiffness of two-piece capsules…
Analytical Testing and Evaluation of Capsules
Figure 13.1Equilibrium moisture content of empty gelatin capsule shells stored at different relative humidities for 2 weeks at 20°C. (Reprinted from Adv Drug Del Rev, 60, Cole ET, Cade D,…
Instrumented Automatic Capsule Filling Machines and Filling Machine Simulation
Figure 7.1A comparison of the original and modified pins of a Harro Hofliger KFM/3 capsule filling machine. (From Moolchandani V. Functionality and Performance of Different Lactose Grades in Capsule Filling:…
An Introduction to Two-Piece Hard Capsules and Their Marketing Benefits
Figure 2.1Capsule shells being formed on mold pins. Figure 2.2Dried capsule shells on mold pins just before removal. After formation, the capsule shells can be printed to improve identification. Printing…
Advances in Capsule Formulation Development and Technology
Figure 1.1Diagrammatic ternary phase diagram for studying the relationship between oil, water and surfactant for self-emulsifying lipid-based drug delivery systems. (Adapted from JB Cannon, MA Long. Emulsions, microemulsions, and lipid-based…
Scale-Up and Transfer of Hard Shell Formulations across Machine Types
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:epub=”http://www.idpf.org/2007/ops”> 11Scale-Up and Transfer of Hard Shell Formulations across Machine Types Larry L. Augsburger and Michael Levin Introduction Scaling Up within the Same Design and Operating Principle Regulatory…
Dry-Fill Formulation and Filling Technology
Figure 8.1The parameters studied for optimization of the formulation and process variables (18) and a representative response surface* (Q10 = percent dissolved in 10 min). (Courtesy of L. Augsburger.) *Response…
TRPA1 Antagonists as Potential Therapeutics for Respiratory Diseases
Chapter 10 TRPA1 Antagonists as Potential Therapeutics for Respiratory Diseases Jessica Tan1,2; Gerald Hunsberger2; Christopher Neipp3; M. Allen McAlexander2,* 1 Department of Biology, College of Science and Technology, Temple University, Philadelphia,…
Mucolipidosis Type IV: Part I
Chapter 24 Mucolipidosis Type IV Part I Ehud Goldin* SENS Research Foundation, Mountain View, CA, USA* Corresponding author: ehud.goldin@sens.org Abstract Mucolipidosis IV is a neurodevelopmental disorder caused by mutations in the…
